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Sexually transmitted infections are among the most common 
communicable conditions and affect the health and lives of people 
worldwide. The World Health Organization (WHO) periodically 
generates estimates to gauge the global burden of four of the most 
common curable sexually transmitted infections: chlamydia 
(etiological agent: Chlamydia trachomatis), gonorrhoea (Neis-
seria gonorrhoeae), trichomoniasis (Trichomonas vaginalis) and 
syphilis (Treponema pallidum).1–6 The estimates provide evidence 
for programme improvement, monitoring and evaluation.
These sexually transmitted infections cause acute urogeni-
tal conditions such as cervicitis, urethritis, vaginitis and genital 
ulceration, and some of the etiological agents also infect the 
rectum and pharynx. Chlamydia and gonorrhoea can cause 
serious short- and long-term complications, including pelvic 
inflammatory disease, ectopic pregnancy, infertility, chronic 
pelvic pain and arthritis, and they can be transmitted during 
pregnancy or delivery. Syphilis can cause neurological, cardio-
vascular and dermatological disease in adults, and stillbirth, 
neonatal death, premature delivery or severe disability in 
infants. All four infections are implicated in increasing the 
risk of human immunodeficiency virus (HIV) acquisition and 
transmission.7 Moreover, people with sexually transmitted 
infections often experience stigma, stereotyping, vulnerability, 
shame and gender-based violence.8
In May 2016, the World Health Assembly adopted the 
Global health sector strategy on sexually transmitted infections, 
2016–2021.9 This strategy includes rapid scale-up of evidence-
based interventions and services to end sexually transmitted 
infections as public health concerns by 2030. The strategy sets 
targets for reductions in gonorrhoea and syphilis incidence in 
adults and recommends the establishment of global baseline 
incidences of sexually transmitted infections by 2018. The pri-
mary objectives of this study were to estimate the 2016 global 
and regional prevalence and incidence of chlamydia, gonor-
rhoea, trichomoniasis and syphilis in adult women and men.
Methods
Prevalence estimation
Chlamydia, gonorrhoea and trichomoniasis
We generated estimates for these three infections through 
systematic reviews using the same methods as for the 2012 
estimates.6
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Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence 
and incidence estimates, 2016
Jane Rowley,a Stephen Vander Hoorn,b Eline Korenromp,c Nicola Low,d Magnus Unemo,e Laith J Abu-
Raddad,f R Matthew Chico,g Alex Smolak,f Lori Newman,h Sami Gottlieb,a Soe Soe Thwin,a Nathalie Brouteta & 
Melanie M Taylora
Objective To generate estimates of the global prevalence and incidence of urogenital infection with chlamydia, gonorrhoea, trichomoniasis 
and syphilis in women and men, aged 15–49 years, in 2016.
Methods For chlamydia, gonorrhoea and trichomoniasis, we systematically searched for studies conducted between 2009 and 2016 reporting 
prevalence. We also consulted regional experts. To generate estimates, we used Bayesian meta-analysis. For syphilis, we aggregated the 
national estimates generated by using Spectrum-STI.
Findings For chlamydia, gonorrhoea and/or trichomoniasis, 130 studies were eligible. For syphilis, the Spectrum-STI database contained 
978 data points for the same period. The 2016 global prevalence estimates in women were: chlamydia 3.8% (95% uncertainty interval, UI: 
3.3–4.5); gonorrhoea 0.9% (95% UI: 0.7–1.1); trichomoniasis 5.3% (95% UI:4.0–7.2); and syphilis 0.5% (95% UI: 0.4–0.6). In men prevalence 
estimates were: chlamydia 2.7% (95% UI: 1.9–3.7); gonorrhoea 0.7% (95% UI: 0.5–1.1); trichomoniasis 0.6% (95% UI: 0.4–0.9); and syphilis 
0.5% (95% UI: 0.4–0.6). Total estimated incident cases were 376.4 million: 127.2 million (95% UI: 95.1–165.9 million) chlamydia cases; 86.9 
million (95% UI: 58.6–123.4 million) gonorrhoea cases; 156.0 million (95% UI: 103.4–231.2 million) trichomoniasis cases; and 6.3 million 
(95% UI: 5.5–7.1 million) syphilis cases.
Conclusion Global estimates of prevalence and incidence of these four curable sexually transmitted infections remain high. The study 
highlights the need to expand data collection efforts at country level and provides an initial baseline for monitoring progress of the World 
Health Organization global health sector strategy on sexually transmitted infections 2016–2021.
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We searched for articles pub-
lished between 1 January 2009 and 29 
July 2018 in PubMed® without lan-
guage restrictions. We used PubMed 
Medical subject heading (MeSH) 
terms for individual country names 
combined with: “chlamydia”[MeSH 
Te r m s ]  O R  “c h l a m y d i a” [ A l l 
Fields],  “gonorrhoea”[All  Fields] 
OR “gonorrhea”[MeSH Terms] OR 
“gonorrhea”[All  Fields],  “tr icho-
monas infections”[MeSH Terms] 
OR (“trichomonas”[All Fields] AND 
“infections”[All Fields]) OR “tricho-
monas infections”[All Fields] OR 
“trichomoniasis”[All Fields]). We also 
asked WHO regional sexually transmit-
ted infection advisors and other leading 
experts in the field for additional pub-
lished and unpublished data. 
To be eligible, studies had to collect 
most specimens between 2009 and 2016 
or be published in 2010 or later if speci-
men collection dates were not available. 
Other study inclusion criteria were: 
sample size of at least 100 individu-
als; general population (e.g. pregnant 
women, women at delivery, women 
attending family planning clinics, men 
and women selected for participation in 
demographic and health surveys); and 
use of an internationally recognized 
diagnostic test with demonstrated pre-
cision using urine, urethral, cervical or 
vaginal specimens.
To reduce bias in the estimation 
of general population prevalence, we 
excluded studies conducted among the 
following groups: patients seeking care 
for sexually transmitted infection or 
urogenital symptoms, women present-
ing at gynaecology or sexual health 
clinics with sexually transmitted infec-
tion related issues, studies restricted to 
women with abnormal Papanicolaou 
test results, remote or indigenous popu-
lations, recent immigrant or migrant 
populations, men who have sex with 
men and commercial sex workers.
Two investigators independently 
reviewed all identified studies to verify 
eligibility. When more than one publica-
tion reported on the same population, 
we retained the publication with the 
most detailed information. For each 
included study, we calculated prevalence 
as the number of individuals with a 
positive test result divided by the total 
number tested. We then standardized 
these values by applying adjustment 
factors for the accuracy of the laboratory 
diagnostic test, study location (rural 
versus urban) and the age of the study 
population. If the adjustments resulted 
in a negative value, we replaced the value 
with 0.1% when doing the meta-analysis. 
The methods and adjustment factors 
were identical to those used to generate 
the 2012 estimates.6
We obtained estimates for 10 geo-
graphical areas (referred to as estimation 
regions).6 Estimates for high-income 
North America (Canada and United 
States of America), were based on the 
latest published United States estimates 
that used data from multiple sources.10,11 
For the other nine estimation regions, 
we calculated a summary prevalence 
estimate by meta-analysis if there were 
three or more data points.12 There were 
sufficient data to generate an estimate for 
chlamydia in women in all regions, but 
not for gonorrhoea or trichomoniasis. 
For regions with insufficient data for 
gonorrhoea and trichomoniasis, we as-
sumed that prevalence was a multiple 
of the prevalence of chlamydia. The 
infection specific multiples were based 
on those studies that met the 2016 in-
clusion criteria (available from the data 
repository).13 For men, when there were 
insufficient data for meta-analysis, the 
prevalence of an infection was assumed 
to be proportional to the prevalence in 
women. The male-to-female ratios were 
infection-specific and were set at the 
same values as in 2012 estimates.6
To reflect the contribution of popu-
lations at higher risk of infection (e.g. 
men who have sex with men and com-
mercial sex workers), who are likely to 
be under-represented in general popula-
tion samples, we increased prevalence 
estimates by 10%, as in the 2012 esti-
mates,6 for each estimation region, apart 
from high-income North America.
We performed the meta-analyses 
using a Bayesian approach with a 
Markov Chain Monte Carlo algorithm 
implemented with the software BRrugs 
in R package (R foundation, Vienna, 
Austria).14 For each infection, the soft-
ware generated 10 000 samples from the 
posterior distribution for the expected 
mean prevalence in each estimation 
region based on the β-binomial model, 
and used these to calculate the 2.5 
and 97.5 uncertainty percentiles.15 We 
calculated global and regional preva-
lence estimates for each infection by 
weighting each of the 10 000 samples 
from estimation regions according to 
population size, using United Nations 
population data for women and men 
aged 15–49 years.16 We present results by 
WHO region, 2016 World Bank income 
classification17 and 2017 sustainable 
development goal (SDG) region.18 All 
analyses were carried out using R sta-
tistical software (R foundation).
Syphilis
We based syphilis estimates on the 
WHO’s published 2016 maternal preva-
lence estimates.19 These estimates were 
generated by using Spectrum-STI, a 
statistical trend-fitting model in the 
publicly available Spectrum suite of 
health policy planning tools20 and 
country specific data from the global 
Spectrum-STI syphilis database (avail-
able from the corresponding author). As 
in the 2012 estimation,6 we assumed that 
the prevalence of syphilis in all women 
15–49 years of age in each country was 
the same as in pregnant women. We then 
increased the estimate by 10% to reflect 
the contribution of populations at higher 
risk. The men to women prevalence ratio 
of syphilis was set at 1.0 and assumed 
to have a uniform distribution ± 33% 
around this value, in agreement with 
data from a recent global meta-analysis 
of syphilis.21
We generated regional and global 
estimates by weighting the contribution 
of each country by the number of wom-
en and men aged 15–49 years. Regional 
and global 95% uncertainty intervals 
(UIs) were generated using the delta 
method;22 uncertainties were assumed to 
be independent across countries.
Incidence estimation
We calculated incidence estimates for 
each infection by dividing prevalence 
by the average duration of infection 
for all estimation regions except high-
income North America where published 
estimates were used.10,11 Estimates of 
the average duration of infection were 
those used in the 2012 estimation6 and 
assumed to have a uniform distribution 
of ± 33.3% around the average duration. 
We calculated uncertainty in incidence 
for a given region, sex and infection 
at the national level using the delta 
method;22 uncertainty in the prevalence 
estimate was multiplied by uncertainty 
in the estimated duration of infection. 
Regional and global uncertainty inter-
vals were generated assuming uncertain-
ties were independent across countries.
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Results
Data availability
Chlamydia, gonorrhoea and trichomoniasis
Of the 7244 articles screened, 112 stud-
ies met the inclusion criteria for one or 
more of the three infections (Fig. 1). 
We identified an additional 18 stud-
ies through expert consultations and 
reviewing reference lists (Nguyen M 
et al., Hanoi Medical University, Viet 
Nam, personal communication, 23 
March 2018; El Kettani A et al., Na-
tional Institute of Hygiene, Morocco, 
personal communication, 2 May 2016; 
Galdavadze K et al., Disease Control 
and Public Health, Republic of Georgia; 
personal communication, 22 August 
2017).23–150 Of these 130 studies, 111 
reported data for women only (Table 1; 
available at: http://www.who.int/bul-
letin/volumes/96/8/18-228486), three 
reported data for men only (Table 2; 
available at: http://www.who.int/bul-
letin/volumes/96/8/18-228486) and 16 
reported data for both women and men 
(Table 1 and Table 2). Only 34 studies in 
women and four studies in men provid-
ed information on all three infections. 
The included studies contained 100 data 
points in women for chlamydia, 64 for 
gonorrhoea and 69 for trichomoniasis. 
In men, there were 16 data points for 
chlamydia, 11 for gonorrhoea and seven 
for trichomoniasis (Table 3).
For women, a total of 43 (21.0%) 
of 205 countries, territories and areas 
had one or more data points for chla-
mydia, 32 (15.6%) for gonorrhoea and 
29 (14.1%) for trichomoniasis. For men, 
only 15 (7.3%) countries, territories and 
areas had one or more data points for 
chlamydia, 10 (4.9%) for gonorrhoea 
and 7 (3.4%) for trichomoniasis. For 
women there were sufficient data to gen-
erate summary estimates for chlamydia 
for the nine estimation regions, but 
not for gonorrhoea or trichomoniasis 
(Table 4).
Syphilis
As of 2 May 2018, the Spectrum-STI 
Database contained 1576 data points 
from surveys conducted since 1990, 
including 978 from January 2009 to De-
cember 2016.151 In total, 181 (88.3%) of 
205 countries, territories and areas had 
sufficient data to generate a Spectrum 
STI estimate for 2016. For the remaining 
24 countries, territories and areas, we 
used the median value of the countries 
with data for the relevant WHO region 
as the 2016 estimate.
Prevalence and incidence 
estimates
Table 5 shows prevalence estimates for 
the WHO regions for 2016. Based on 
prevalence data from 2009 to 2016, the 
estimated pooled global prevalence of 
chlamydia in 15–49-year-old women 
was 3.8% (95% UI: 3.3–4.5) and in 
men 2.7% (95% UI: 1.9–3.7), with re-
gional values ranging from 1.5 to 7.0% 
in women and 1.2 to 4.0% in men. For 
gonorrhoea, the global estimate was 
0.9% (95% UI: 0.7–1.1) in women and 
0.7% (95% UI: 0.5–1.1) in men, with re-
gional values in women ranging from 0.3 
to 1.9% and from 0.3 to 1.6% in men. The 
estimates for trichomoniasis were 5.3% 
(95% UI: 4.0–7.2) in women and 0.6% 
(95% UI: 0.4–0.9) in men, with regional 
values ranging from 1.6 to 11.7% in 
women and from 0.2 to 1.3% in men. For 
syphilis, the global estimate in both men 
and women was 0.5% (95% UI: 0.4–0.6) 
with regional values ranging from 0.1 
to 1.6%. The WHO African Region had 
the highest prevalence for chlamydia in 
men, gonorrhoea in women and men, 
trichomoniasis in women and syphilis 
in men and women. The WHO Region 
of the Americas had the highest preva-
lence of chlamydia in women and of 
trichomoniasis in men.
These prevalence estimates cor-
respond to the totals of 124.3 million 
cases of chlamydia, 30.6 million cases 
of gonorrhoea, 110.4 million cases of 
trichomoniasis and 19.9 million cases 
of syphilis (available from the data 
repository).13
Using the World Bank classification, 
high-income countries, territories and 
areas had the lowest estimated preva-
lence, and low-income countries, ter-
ritories and areas had the highest preva-
lence of gonorrhoea, trichomoniasis 
and syphilis. For chlamydia, estimated 
prevalence was highest in upper-middle 
income countries, territories and areas 
(Fig. 2). The SDG grouping showed 
the highest prevalence of all four sexu-
ally transmitted infections in Oceania 
region, that is, Pacific island nations 
excluding Australia and New Zealand 
(available from the data repository).13 
We estimated the global incidence 
rate for chlamydia in 2016 to be 34 cases 
per 1000 women (95% UI: 25–45) and 
33 per 1000 men (95% UI: 21–48); for 
gonorrhoea 20 per 1000 women (95% 
Fig. 1. Flowchart of the selection of studies for estimating the prevalence and incidence 
of chlamydia, gonorrhoea and trichomoniasis, 2016




718 full-text articles screened
112 eligible studies
130 studies included in review
4833 duplicates or articles did not 
meet the inclusion criteria
1693 articles did not meet the 
inclusion criteria
597 articles did not meet the 
inclusion criteria
18 articles provided by WHO 
Regional Advisors and other 
sexually transmitted infection 
experts or identified from 
reference lists
WHO: World Health Organization.
Note: This figure does not include studies from North America; the North American estimates were based 
on published estimates.10,11
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UI: 14–28) and 26 per 1000 men (95% 
UI: 15–41); for trichomoniasis 40 per 
1000 women (95% UI: 27–58) and 42 
per 1000 men (95% UI: 23–69); and for 
syphilis 1.7 per 1000 women (95% UI: 
1.4–2.0) and 1.6 per 1000 men (95% UI: 
1.3–1.9; Fig. 3). The WHO Region of 
the Americas had the highest incidence 
rate for chlamydia and syphilis in both 
women and men, while the WHO Af-
rican Region had the highest incidence 
rates for gonorrhoea and trichomoniasis 
in women and men. Incidence rates by 
income category and SDG regions are 
available from the data repository.13
These incidence rates translate 
globally into 127.2 million (95% UI: 
95.1–165.9) new chlamydia cases, 86.9 
million (95% UI: 58.6–123.4 million) 
gonorrhoea cases, 156.0 million (95% 
UI: 103.4–231.2 million) trichomoniasis 
cases and 6.3 million (95% UI: 5.5–7.1 
million) syphilis cases in women and 
men aged 15–49 years in 2016. Together, 
the four infections accounted for 376.4 
million new infections in 15–49-year-
old people in 2016. Approximately 
13.5% (50.8 million) of these infections 
occurred in low-income countries, 
territories and areas, 31.4% (118.1 mil-
lion) in lower middle income, 47.1% 
(177.3 million) in upper-middle income 
and 8.0% (30.1 million) in high-income 
(available from the data repository).13
Comparison of estimates
Comparing the 2012 estimates with 
the estimates presented here shows 
that more data points were available 
in women for the 2016 estimates. The 
number increased from 69 to 100 for 
chlamydia, 50 to 64 for gonorrhoea and 
44 to 69 for trichomoniasis. For men, 
the number of data points fell from 
21 to 16 for chlamydia and from 12 to 
11 for gonorrhoea, but increased from 
one to seven for trichomoniasis. The 
period of eligibility for both estimates 
was eight years with an overlap of four 
years (2009 to 2012); in women 27 data 
points were included in both estimates 
for chlamydia, 18 for gonorrhoea and 20 
for trichomoniasis. In men, these over-
laps were six, five and one, respectively.
Table 5 compares the 2012 and 
2016 prevalence estimates for the four 
infections. For syphilis, two estimates 
are presented for 2012, the published 
estimate6 and the 2012 estimate gener-
ated using Spectrum STI and the latest 
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a  In consultation with advisors on sexual transmitted infections for the World Health Organization (WHO) Region of the Americas, we decided to use the midpoint 
between the 2016 estimate generated by applying the global male-to-female ratio (7.5%) and the 2012 estimate for the region (2.1%). We deemed the former to be 
too high and the latter too low.
b  Following discussions with the United States Centers for Disease Control and Prevention, we based our estimates on the latest published United States national 
estimates21,22 and assumed they remained constant over time and that estimates for 15–39-year-old people could be extrapolated to the 15–49-year age range. We 
did not apply the adjustments used for other Regions in the WHO estimates process. The figures for the United States were also applied to Canada.
c  The estimate based on the three available data points was over 4%, considerably higher than the 2012 estimate. Following discussions with regional experts we 
decided not to use this estimate, but instead to use the trichomoniasis to chlamydia ratio for low and lower middle-income countries, territories and areas.
d  This estimation region is made up of countries from East Asia and South East Asia. We used the higher and upper-middle income gonorrhoea to chlamydia ratio for 
East Asia and the low and lower-middle income ratio for South East Asia.” 
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Spectrum data set.19 For all infections in 
both women and men, the 2016 global 
prevalence estimate was within the 
95% UI for 2012. At the regional level, 
the 95% UIs for prevalence overlapped 
for all four infections in both men and 
women, apart from gonorrhoea in men 
in the WHO African Region which was 
higher in 2016 than in 2012.
Discussion
We estimated a global total of 376.4 mil-
lion new curable urogenital infections 
with chlamydia, gonorrhoea, tricho-
moniasis and syphilis in 15–49-year-old 
women and men in 2016. This estimate 
corresponds to an average of just over 
1 million new infections each day. The 
number of individuals infected, how-
ever, is smaller as repeat infections and 
co-infections are common.152
The estimates of prevalence and in-
cidence in 2016 were similar to those in 
2012, both globally and by region, show-
ing that sexually transmitted infections 
are persistently endemic worldwide. 
Grouping countries, territories and ar-
eas according to SDG regions revealed 
that the prevalence and incidence of all 
four sexually transmitted infections, in 
both women and men, were highest in 
the Oceania Region. The small island 
states in this SDG region are part of the 
WHO Western Pacific Region, which 
is dominated by China (owing to its 
population size). Therefore, the levels 
of sexually transmitted infections and 
need for infection control in these island 
states are masked when viewing the 
estimates only by WHO Region. When 
using the World Bank classification of 
countries, the prevalence of gonorrhoea, 
trichomoniasis and syphilis were high-
est in low-income countries, territories 
and areas. The prevalence of chlamydia 
was highest in the upper middle-income 
countries, territories and areas, partly 
due to high estimates in some Latin 
American countries. Further research 
is needed to determine whether these 
estimates reflect methodological fac-
tors or differences in C. trachomatis 
transmission.
The 2016 estimates for chlamydia, 
gonorrhoea and trichomoniasis were 
based on a systematic review of the 
literature complemented by outreach 
to experts using the same methods as 
in 2012. The aim was to reduce bias 
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search for data.19 For syphilis, the use 
of national estimates generated by a 
statistical model improves on the 2012 
method by making use of historical 
trend data. The similarity between the 
published 2012 syphilis estimates and 
Spectrum STI generated estimates for 
2012 provides reassurance about the 
validity of comparing the 2016 and 2012 
estimates.
The study has limitations. First, 
limited prevalence data were available, 
despite an eight-year time window for 
data inclusion. Estimates for a given 
infection and region are therefore ex-
trapolated from a small number of data 
points and ratios were used to generate 
estimates for some regions. For men, 
the lack of data was particularly strik-
ing. For syphilis, most data were from 
pregnant women, which might not 
reflect all women aged 15–49 years, or 
men. Second, the source studies include 
people in different age groups and used a 
range of diagnostic tests, so adjustment 
factors were applied to standardize mea-
sures across studies. Third, owing to the 
absence of empirical studies, incidence 
estimates were derived from the rela-
tionship between prevalence and dura-
tion of infection, and data on the average 
duration of infection for each of the 
four infections are also limited. Finally, 
because only studies among the general 
population were used, the prevalence 
and incidence in areas where key popu-
lations contribute disproportionately to 
sexually transmitted infection epidemics 
may have been underestimated despite 
the applied correction factor. These 
limitations have been discussed previ-
ously in detail.6
This study has implications for 
sexually transmitted infection program-
ming and research. The quantity and 
quality of prevalence and incidence 
studies for sexually transmitted infec-
tions in representative samples of the 
general population, for both women and 
men, need improvement. Identifying 
opportunities to integrate data collec-
tion with clinical care platforms, such 
as HIV, adolescent, maternal, family 
planning and immunization is crucial. 
The recently developed WHO protocol 
for assessing the prevalence of sexually 
transmitted infections in antenatal care 
settings153 provides a framework and 
consistent methods that can be adapted 
for women and men. Comparing data 
across studies requires better under-
standing of the performance characteris-
tics of diagnostic tests, and implications 
for estimates of the average duration of 
infection for each infection. The pro-
cesses for producing future prevalence 
estimates could be made timelier and 
more efficient through continually up-
dated systematic reviews,154 as well as 
technological solutions that automate 
searching of databases and facilitate high 
quality updates of reviews.
The global estimates of prevalence 
and incidence of four curable sexually 
transmitted infections are important in 
the broader global context, highlighting 
a continuing public health challenge. 
Prevalence and incidence data play an 
important role in the design and evalu-
ation of programmes and interventions 
for sexually transmitted infections 
and in interpreting changes in HIV 
epidemiology. The global threat of an-
timicrobial resistance, particularly the 
emergence of N. gonorrhoeae resistance 
to the few remaining antimicrobials 
recommended for treatment, further 
highlights the importance of invest-
ing in monitoring prevalence and 
incidence.155 Estimates of prevalence 
and incidence are essential for calcu-
lations of the burden of disease due to 
sexually transmitted infections, which 
are needed to advocate for funding to 
support sexually transmitted infection 
programmes. These burden estimates 
can also be used to promote innova-
tion for point-of-care diagnostics, new 
therapeutics, vaccines and microbi-
cides. The WHO Global Health Sector 
Fig. 2. Prevalence estimates of chlamydia, gonorrhoea, trichomoniasis and syphilis in 
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Notes: We defined adults as 15–49 years of age and used year 2016 income classification from the World 
Bank.17
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Strategy on Sexually Transmitted Infec-
tions sets a target of 90% reductions 
in the incidence of gonorrhoea and of 
syphilis, globally, between 2018 and 
2030.9 Major scale-ups of prevention, 
testing, treatment and partner services 
will be required to achieve these goals. 
The estimates generated in this paper, 
despite their limitations, provide an 
initial baseline for monitoring progress 
towards these ambitious targets. ■
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صخلم
2016 ،ةيلماعلا ةباصلإاو راشتنلاا تاريدقت :يرهزلاو ،تارعشلما ءادو ،نلايسلاو ،ايديملاكلا
 زاهلجا ىودعل ةيلماعلا ةباصلإاو راشتنلال تاريدقت عضو ضرغلا
 ،تارعشلما ءادو ،نلايسلاو ،ايديملاكلا ضارمأو ،ليسانتلا ليوبلا
 15  ينب  مهرماعأ  حواترت  نيذلا  ،لاجرلاو  ءاسنلا  ىدل  يرهزلاو
.2016 ماع في ،ةنس 49و
 انمق دقف ،تارعشلما ءادو ،نلايسلاو ،ايديملاكلل ةبسنلاب  ةقيرطلا
 ةترفلا  للاخ  تتم  يتلا  تاساردلا  نع  يجهنم  لكشب  ثحبلاب
 انمق  ماك  .راشتنلاا  ىدم  حضوت  يتلاو  2016  لىإ  2009  نم
 مادختساب  انمق  ،تاريدقتلا  عضولو  .ينيميلقإ  ءابرخ  ةراشتساب
 عيمجتب انمق ،يرهزلا ضرلم ةبسنلاب .Bayesian يولتلا ليلحتلا
.Spectrum-STI مادختسا نع ةتجانلا ةينطولا تاريدقتلا
 ،تارعشلما  ءادو  ،نلايسلاو  ،ايديملاكلا  ضارملأ  ةبسنلاب  جئاتنلا
 توتحا ،يرهزلا ضرلم ةبسنلابو .ةلهؤم ةسارد 130 كانه تناك
 سفنل  تانايب  ةطقن  978  لىع  Spectrum-STI  تانايب  ةداق
 :ءاسنلا في 2016  ماع في يلماعلا راشتنلاا تاريدقت تناك .ةترفلا
 ،(4.5  لىإ  3.3  :95%  ةقثلا  مدع  لصاف)  3.8%  ايديملاكلا
 ،(1.1  لىإ  0.7  :95%  ةقثلا  مدع  لصاف)  0.9%  نلايسلاو
 ؛(7.2 لىإ 4.0 :95% ةقثلا مدع لصاف) 5.3% تارعشلما ءادو
 تناك .(0.6 لىإ 0.4 :95% ةقثلا مدع لصاف) 0.5% يرهزلاو
 2.7%  ايديملاكلا  :لاجرلا  في  2016  ماع  في  راشتنلاا  تاريدقت
 لصاف) 0.7% نلايسلاو ،(3.7 لىإ 1.9 :95% ةقثلا مدع لصاف)
 لصاف) 0.6% تارعشلما ءادو ،(1.1 لىإ 0.5 :95% ةقثلا مدع
 مدع لصاف)  0.5%  يرهزلاو ،(0.9  لىإ 0.4 :95%  ةقثلا  مدع
 يريدقتلا  ةباصلإا  تلااح عوممج غلب  .(0.6–0.4 :95%  ةقثلا
 :95%  ةقثلا  مدع  لصاف)  نويلم  127.2  :ةلاح  نويلم  376.4
 نويلم  86.9  ؛ايديملاكلا  تلااح  (نويلم  165.9  لىإ  95.1
 تلااح  (نويلم  123.4  لىإ  58.6  :95%  ةقثلا  مدع  لصاف)
 لىإ  103.4  :95%  ةقثلا  مدع  لصاف)  نويلم  156.0  ؛نلايسلا
Fig. 3. Incidence rate estimates for chlamydia, gonorrhoea, trichomoniasis and syphilis 






































































Chlamydia Gonorrhoea Trichomoniasis Syphilis 95% UI
UI: uncertainty interval, WHO: World Health Organization.
Note: We defined adults as 15–49 years of age.
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摘要
衣原体病、淋病、滴虫病和梅毒 :2016 年全球患病率和发病率估计
目的 旨在估计 2016 年 15-49 岁男女泌尿生殖系统感染
衣原体病、淋病、滴虫病和梅毒的全球患病率和发病
率。
方法 对于衣原体病、淋病和滴虫病 , 我们系统搜索
了 2009 年至 2016 年间的患病率报告研究。我们还咨
询了区域专家。为了生成估计值 , 我们使用了贝叶斯
荟萃分析。对于梅毒 , 我们汇总分析了使用 Spectrum-
STI 生成的全国估计值。
结果 对 于 衣 原 体 病、 淋 病 和 / 或 滴 虫 病 , 符 合 要
求 的 有 130 项 研 究。 对 于 梅 毒 , Spectrum-STI 数 据
库 包 含 了 同 一 时 期 的 978 个 数 据 点。2016 年 , 全
球 女 性 患 病 率 估 计 值 为 : 衣 原 体 病 3.8%(95% 不 确
定 区 间 ,UI:3.3-4.5); 淋 病 0.9%(95% UI:0.7–1.1); 滴 虫
病 5.3%(95% UI:4.0–7.2) 和 梅 毒 0.5%(95% UI:0.4-0.6)。
全球男性患病率估计值为 : 衣原体病 2.7%(95% UI:1.9-
3.7); 淋病 0.7%(95% UI:0.5-1.1); 滴虫病 0.6%(95% UI:0.4-
0.9); 梅 毒 0.5%(95% UI:0.4-0.6)。 预 计 病 例 总 数
为 3.764 亿 :1.272 亿 (95% UI:9510-16590 万 ) 衣 原
体 病 病 例 ;8690 万 (95% UI:5860-12340 万 ) 淋 病 病
例 ;15600 万 (95% UI:10340-23120 万 ) 滴虫病病例 ;630 万
(95% UI:550-710 万 ) 梅毒病例。
结论 对这四种可治愈的性传播疾病的患病率和发病率
的全球估计值仍然很高。该研究强调了扩大国家级数




Chlamydiose, gonorrhée, trichomonase et syphilis: estimations de la prévalence et de l'incidence mondiales, 2016
Objectif Produire des estimations de la prévalence et de l'incidence 
mondiales des infections urogénitales dues à la chlamydiose, à la 
gonorrhée, à la trichomonase et à la syphilis chez les femmes et les 
hommes de 15 à 49 ans, en 2016.
Méthodes Pour la chlamydiose, la gonorrhée et la trichomonase, nous 
avons systématiquement recherché les études menées entre 2009 et 
2016 qui s’intéressaient à la prévalence. Nous avons également consulté 
des experts régionaux. Pour produire des estimations, nous avons eu 
recours à une méta-analyse bayésienne. Pour la syphilis, nous avons 
regroupé les estimations nationales obtenues à l'aide de Spectrum-STI.
Résultats Pour la chlamydiose, la gonorrhée et/ou la trichomonase, 
130 études étaient éligibles. Pour la syphilis, la base de données 
de Spectrum-STI contenait 978 points de données pour la période 
considérée. Les estimations de la prévalence mondiale en 2016 chez les 
femmes étaient les suivantes: chlamydiose 3,8% (intervalle d'incertitude 
de 95%, II: 3,3–4,5); gonorrhée 0,9% (II 95%: 0,7–1,1); trichomonase 5,3% 
(II 95%: 4,0–7,2); et syphilis 0,5% (II 95%: 0,4–0,6). Chez les hommes, les 
estimations de la prévalence étaient les suivantes: chlamydiose 2,7% (II 
95%: 1,9-3,7); gonorrhée 0,7% (II 95%: 0,5-1,1); trichomonase 0,6% (II 
95%: 0,4-0,9); et syphilis 0,5% (II 95%: 0,4–0,6). L'incidence totale estimée 
était de 376,4 millions de cas: 127,2 millions (II 95%: 95,1–165,9 millions) 
de cas de chlamydiose; 86,9 millions (II 95%: 58,6-123,4 millions) de cas 
de gonorrhée; 156,0 millions (II 95%: 103,4-231,2 millions) de cas de 
trichomonase; et 6,3 millions (II 95%: 5,5–7,1 millions) de cas de syphilis.
Conclusion Les estimations mondiales de la prévalence et de l'incidence 
de ces quatre infections sexuellement transmissibles guérissables restent 
élevées. Cette étude souligne la nécessité d'amplifier les efforts de 
collecte de données au niveau des pays et offre un point de référence 
pour suivre la progression de la Stratégie mondiale du secteur de la santé 
contre les IST 2016–2021 de l'Organisation mondiale de la Santé. 
Резюме
Хламидии, гонорея, трихомониаз и сифилис: распространенность в мире и оценка частоты 
заболеваний в 2016 году
Цель Оценить распространенность в мировом масштабе и 
частоту урогенитальных инфекций, вызываемых хламидией, а 
также гонореи, трихомониаза и сифилиса у мужчин и женщин в 
возрасте от 15 до 49 лет по состоянию на 2016 год.
Методы Для хламидиоза, гонореи и трихомониаза авторы 
провели систематический поиск исследований, выполненных 
в период с 2009 по 2016 год, в которых приводились 
данные по распространенности заболеваний. Авторы также 
консультировались с международными специалистами. 
Для оценки использовался байесовский метаанализ. Для 
исследования сифилиса нами были объединены национальные 
оценки, созданные с использованием методики Spectrum-STI.
Результаты Было обнаружено 130 исследований на тему 
хламидийной инфекции, гонореи и (или) трихомониаза. 
Что касается сифилиса, база данных Spectrum-STI за тот же 
период содержала 978 источников данных. По состоянию на 
2016 год распространенность изучаемых заболеваний в мире 
среди женщин составляла: хламидиоз 3,8% (95%-й интервал 
неопределенности, ИН: 3,3–4,5), гонорея 0,9% (95%-й ИН: 0,7–1,1), 
трихомониаз 5,3% (95%-й ИН: 4,0–7,2) и сифилис 0,5% (95%-й ИН: 
0,4–0,6). У мужчин распространенность хламидиоза составила 
2,7% (95%-й ИН: 1,9–3,7), гонореи 0,7% (95%-й ИН: 0,5–1,1), 
трихомониаза 0,6% (95%-й ИН: 0,4–0,9) и сифилиса 0,5% (95%-
й ИН: 0,4–0,6). Общее приблизительное количество случаев 
заболевания составило 376,4 млн человек: 127,2 млн (95 %-й 
ИН: 95,1–165,9 млн) случаев хламидийной инфекции, 86,9 млн 
(95%-й ИН: 58,6–123,4 млн) случаев гонореи, 156,0 млн (95%-й 
 مدع لصاف)  نويلم 6.3  ؛تارعشلما ءاد تلااح (نويلم 231.2
.يرهزلا تلااح (نويلم 7.1 لىإ 5.5 :95% ةقثلا
 هذبه ةباصلإاو راشتنلا ةيلاع ةيلماعلا تاريدقتلا لازت لا جاتنتسلاا
 ةساردلا  طلست  .اهنم  جلاعلاو  ًايسنج  ةلوقنلما  ةعبرلأا  ضارملأا
 ىوتسم  لىع  تانايبلا  عجم  دوهج  عيسوت  لىإ  ةجالحا  لىع  ءوضلا
 ةيجيتاترسإ في زرحلما مدقتلا ةبقارلم ليوأ ساسأ طخ رفوتو ،لودلا
 ضارملأا نأشب ةيلماعلا ةحصلا ةمظنلم عباتلا ةيلماعلا ةحصلا عاطق
 .2021 لىإ 2016 نم ةترفلا للاخ ًايسنج ةلوقنلما
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ИН: 103,4–231,2 млн) случаев трихомониаза и 6,3 млн (95%-й ИН: 
5,5–7,1 млн) случаев сифилиса.
Вывод Оценки мировой распространенности и частоты 
этих четырех излечимых инфекций, передаваемых половым 
путем (ИППП), остаются высокими. Исследование показывает 
необходимость предпринимать дальнейшие усилия по сбору 
данных на уровне каждой страны и может служить источником 
базовых значений для мониторинга прогресса в исполнении 
глобальных стратегий ВОЗ в секторе здравоохранения 
относительно ИППП на период 2016–2021 гг. 
Resumen
Clamidia, gonorrea, tricomoniasis y sífilis: estimaciones de prevalencia e incidencia mundiales, 2016
Objetivo Generar estimaciones de la prevalencia y la incidencia 
mundiales de la infección urogenital por clamidia, gonorrea, 
tricomoniasis y sífilis en mujeres y hombres de 15 a 49 años de edad 
en 2016.
Métodos Para la clamidia, la gonorrea y la tricomoniasis, se realizaron 
búsquedas sistemáticas de estudios realizados entre 2009 y 2016 que 
registrasen la prevalencia. También se consultó a expertos regionales. 
Para generar estimaciones, se utilizó el metanálisis bayesiano. Para la 
sífilis, se añadieron las estimaciones nacionales generadas por el uso 
de Spectrum-STI.
Resultados Para la clamidia, la gonorrea y/o la tricomoniasis, hubo 
130 estudios que cumplían los criterios. Para la sífilis, la base de datos 
Spectrum-STI contenía 978 puntos de datos para el mismo periodo. 
Las estimaciones de prevalencia mundial en mujeres en 2016 fueron: 
clamidia 3,8 % (intervalo de incertidumbre, II, del 95 %: 3,3-4,5); gonorrea 
0,9 % (II del 95 %: 0,7-1,1); tricomoniasis 5,3 % (II del 95 %: 4,0-7,2); y 
sífilis 0,5 % (II del 95 %: 0,4-0,6). Las estimaciones de prevalencia en 
hombres fueron: clamidia 2,7 % (intervalo de incertidumbre, II, del 
95 %: 1,9-3,7); gonorrea 0,7 % (II del 95 %: 0,5-1,1); tricomoniasis 0,6 % 
(II del 95 %: 0,4-0,9); y sífilis 0,5 % (II del 95 %: 0,4-0,6). El total estimado 
de casos incidentes fue de 376,4 millones: 127,2 millones (II del 95 %: 
95,1-165,9 millones) de casos de clamidia; 86,9 millones (II del 95 %: 
58,6-123,4 millones) de casos de gonorrea; 156,0 millones (II del 95 %: 
103,4-231,2 millones) de casos de tricomoniasis; y 6,3 millones (II del 
95 %: 5,5-7,1 millones) de casos de sífilis.
Conclusión Las estimaciones mundiales de la prevalencia y la incidencia 
de estas cuatro enfermedades de transmisión sexual curables siguen 
siendo elevadas. El estudio destaca la necesidad de ampliar los esfuerzos 
de recopilación de datos a nivel nacional y proporciona una base inicial 
para el seguimiento de los progresos de la Estrategia Mundial del Sector 
de la Salud de la Organización Mundial de la Salud sobre las ETS entre 
2016 y 2021.
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